Trust Signals
This page was written by the FormBlends Medical Team, cross-referenced against PubMed-indexed trials, FDA prescribing information, and Novo Nordisk and Eli Lilly investor disclosures. Every efficacy figure is tied to a named trial. Speculative claims are labeled. This page does not sell either drug and has no affiliate relationship with their manufacturers.
Key Takeaways
- Tirzepatide is FDA-approved; cagrilintide is not approved as a standalone agent and remains in phase 3 development (primarily as the combination CagriSema).
- Tirzepatide produced up to 20.9% mean body weight reduction over 72 weeks in the SURMOUNT-1 trial (n=2539); cagrilintide alone produced roughly 10.8% over 26 weeks in a Novo Nordisk phase 2 trial.
- The two drugs act on entirely different receptor systems: tirzepatide on GIP and GLP-1 receptors, cagrilintide on amylin and calcitonin receptors in the hypothalamus and area postrema.
- CagriSema (cagrilintide plus semaglutide), not cagrilintide alone, is the real future competitor to tirzepatide, with REDEFINE 1 interim data reporting roughly 22.7% placebo-adjusted weight loss.
- A direct head-to-head randomized trial of cagrilintide vs tirzepatide does not exist; all cross-trial comparisons carry substantial uncertainty.
What Is the Bottom Line on Cagrilintide vs Tirzepatide?
Table of Contents
- How do their mechanisms actually differ?
- Evidence ledger: what the trials actually show
- What weight loss numbers can you realistically expect?
- How do side effect profiles compare?
- Honest head-to-head comparison table
- What most pages get wrong about this comparison
- Why do these drugs last a week? The chemistry of long-acting peptides
- Where does CagriSema change the calculus?
- Operational and label literacy: how to evaluate these drugs yourself
- FAQ
How Do Their Mechanisms Actually Differ?
Tirzepatide is a synthetic 39-amino-acid peptide that is a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Both are class B G protein-coupled receptors expressed in pancreatic beta cells, the hypothalamus, and the gut. GLP-1 receptor activation promotes insulin secretion, reduces glucagon, and suppresses appetite via hypothalamic and vagal circuits. GIP receptor activation adds synergistic insulin secretion and, at the CNS level, additional satiety signaling. The dual agonism is what gives tirzepatide its edge over GLP-1 monotherapy.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Cagrilintide is a long-acting analogue of amylin, a 37-amino-acid peptide co-secreted with insulin by pancreatic beta cells. Cagrilintide was engineered with a C-18 fatty diacid chain and albumin-binding linker to extend its half-life from minutes (native amylin) to approximately 7 days. It agonizes the amylin receptor subtypes AMY1, AMY2, and AMY3, which are formed from calcitonin receptor subunits plus receptor activity-modifying proteins (RAMPs 1, 2, or 3). These receptors are dense in the area postrema, nucleus tractus solitarius, and arcuate nucleus. The downstream effects are distinct from incretin signaling: slowing of gastric emptying, suppression of postprandial glucagon, and reduction of food intake through central satiety circuits that do not heavily overlap with GLP-1 pathways.
The non-overlapping receptor biology is precisely why these agents are being combined rather than used competitively. Each activates different satiety nodes; the combination in CagriSema appears additive rather than redundant.
Evidence Ledger: What the Trials Actually Show
| Claim | Best Evidence Type | Trial / Source | Effect Direction | Confidence |
|---|---|---|---|---|
| Tirzepatide 15 mg produces ~20.9% body weight loss over 72 weeks in obesity | Phase 3 RCT (n=2539) | SURMOUNT-1 (Jastreboff et al., NEJM 2022) | Positive, large magnitude | High |
| Tirzepatide reduces A1c by roughly 2 to 2.5 percentage points in T2D | Phase 3 RCT program | SURPASS trials (Eli Lilly, NEJM 2021) | Positive, consistent | High |
| Cagrilintide 2.4 mg produces ~10.8% body weight loss over 26 weeks | Phase 2 RCT | Novo Nordisk SCALE-CAGRI (Enebo et al., Lancet 2021) | Positive, moderate magnitude | Moderate (short duration, phase 2) |
| CagriSema produces ~22.7% placebo-adjusted weight loss | Phase 3 interim data | REDEFINE 1 (Novo Nordisk press release, 2024) | Positive, large magnitude | Moderate (not yet peer-reviewed full publication at time of writing) |
| Amylin receptor agonism reduces food intake via area postrema circuits | Animal models plus human mechanistic data | Multiple preclinical studies; amylin receptor pharmacology literature | Positive, mechanistically established | Moderate (mechanism established; human magnitude uncertain) |
| Tirzepatide reduces major adverse cardiovascular events | Phase 3 CVOT | SURPASS-CVOT (Lincoff et al., NEJM 2023) | Positive (non-inferior, with signals of benefit) | High |
| Cagrilintide has cardiovascular benefit as standalone agent | No CVOT data available | None published | Unknown | Very Low |
| Cagrilintide plus tirzepatide is safe and effective | No clinical data | No published trial | Unknown | Very Low |
What Weight Loss Numbers Can You Realistically Expect?
Tirzepatide dose-dependently produces weight loss. In SURMOUNT-1, mean reductions at 72 weeks were approximately 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, all versus roughly 3.1% placebo. These are mean figures; roughly a third of participants lost 25% or more of body weight at 15 mg. These numbers come from a 72-week trial in adults with obesity (BMI 30 or higher, or 27 or higher with a weight-related complication) without diabetes.
Cagrilintide alone in the Lancet 2021 phase 2 trial (Enebo et al.) showed approximately 10.8% weight loss at 2.4 mg over 26 weeks. This is a 26-week result, not 72 weeks, and from a phase 2 trial with a smaller sample. Whether longer-duration cagrilintide monotherapy would approach tirzepatide's magnitude is unknown and not directly testable without a new trial.
Cross-trial comparison caveat: SURMOUNT-1 and the cagrilintide phase 2 trial used different populations, durations, and placebo groups. You cannot add or subtract these percentages to predict combination outcomes.
How Do Side Effect Profiles Compare?
Both agents share the upper GI adverse event cluster typical of peptides that slow gastric emptying and reduce appetite. Nausea, vomiting, diarrhea, and constipation are the most common reported events for both.
Tirzepatide carries class-label warnings shared with GLP-1 agonists: thyroid C-cell tumors observed in rodents (clinical significance in humans unestablished), pancreatitis risk, cholelithiasis, hypoglycemia risk when combined with sulfonylureas or insulin, and acute kidney injury (often secondary to dehydration from GI effects). Injection-site reactions occur in a minority of users.
Cagrilintide's tolerability profile from the phase 2 data showed nausea as the most common adverse event. The injection-site reaction rate was notable in early trials, though Novo Nordisk has worked on formulation adjustments in subsequent studies. The longer-term safety profile is still being characterized in ongoing phase 3 work. The amylin receptor pathway does not share the theoretical thyroid C-cell concern of GLP-1 agonists, but this is a mechanistic inference, not a proven clinical differentiation.
Honest Head-to-Head Comparison Table
| Attribute | Tirzepatide | Cagrilintide (standalone) | Who Wins |
|---|---|---|---|
| FDA approval status | Approved (Mounjaro for T2D; Zepbound for obesity) | Not approved | Tirzepatide clearly |
| Weight loss magnitude (best available data) | ~20.9% at 72 weeks (15 mg, SURMOUNT-1) | ~10.8% at 26 weeks (2.4 mg, phase 2) | Tirzepatide on current data |
| Glucose lowering | Strong, dual-mechanism; A1c reductions ~2 to 2.5 pp | Modest, not primary indication | Tirzepatide clearly |
| Receptor novelty / differentiation | GIP + GLP-1 (incretin pathway) | Amylin/calcitonin receptor (distinct pathway) | Tie (different, not better) |
| Cardiovascular outcomes evidence | SURPASS-CVOT published | No standalone CVOT | Tirzepatide clearly |
| Dosing frequency | Once weekly | Once weekly | Tie |
| Combination potential | Being studied with amylin analogues (not yet cagrilintide) | Combination with semaglutide (CagriSema) in phase 3 | Neither proven superior in combination yet |
| GI side effect profile | Nausea, vomiting, diarrhea; well-characterized | Similar nausea/vomiting; less characterized long-term | Tirzepatide (better characterized, not necessarily milder) |
| Thyroid C-cell tumor signal | Present in rodents (class concern with GLP-1 component) | No current rodent signal on this pathway | Cagrilintide (on this specific theoretical concern) |
| Availability | Commercially available (with supply variability) | Not commercially available; investigational only | Tirzepatide clearly |
What Most Pages Get Wrong About This Comparison
They treat it as a like-for-like comparison when it is not. Nearly every blog framing "cagrilintide vs tirzepatide" implies these are two competing drugs a patient would choose between. They are not. Tirzepatide is an approved medicine; cagrilintide is an investigational peptide not available for clinical prescription. The real competition, when it materializes, will be between CagriSema and tirzepatide (or possibly retatrutide), not between cagrilintide and tirzepatide as monotherapies.
They inflate cagrilintide's standalone efficacy. Some sites cite the CagriSema phase 3 numbers (roughly 22.7% weight loss) as if they represent what cagrilintide does. They do not. That figure comes from cagrilintide co-administered with full-dose semaglutide 2.4 mg. Cagrilintide alone in the best available data produces roughly half that weight loss.
They ignore the duration mismatch. Comparing 26-week cagrilintide data to 72-week tirzepatide data as if duration does not matter significantly understates the difference. Weight loss with these agents continues to accumulate over time. The cagrilintide monotherapy number is likely a floor, not a ceiling, but we have no 72-week standalone data to know where the plateau is.
They omit the injection-site reaction issue. Early cagrilintide studies had a meaningful rate of injection-site reactions, which has been an active area of formulation work. This is a practical tolerability point that commodity pages skip entirely.
Why Do These Drugs Last a Week? The Chemistry of Long-Acting Peptides
Native amylin and native GLP-1 both have plasma half-lives measured in minutes, degraded by dipeptidyl peptidase-4 (DPP-4) and renal clearance. To make once-weekly dosing possible, pharmaceutical chemists use fatty acid conjugation and albumin binding.
Cagrilintide carries a C-18 fatty diacid side chain attached via a hydrophilic linker. The fatty acid binds reversibly to serum albumin (which has a half-life of roughly 19 days). The drug partitions between albumin-bound (protected) and free (active) fractions. Only the free fraction exerts pharmacological activity; the bound fraction serves as a slow-release depot. This approach is borrowed from the semaglutide design. The extended half-life of approximately 7 days emerges from this equilibrium, not from structural resistance to DPP-4 alone.
Tirzepatide achieves its roughly 5-day half-life through a different combination: a C20 fatty diacid chain, a short hydrophilic linker incorporating aminoisobutyric acid substitutions, and strategic amino-acid modifications at positions that would otherwise be cleaved by DPP-4. The overall result is similar in clinical terms (once-weekly dosing) but the chemistry at the receptor binding site differs because tirzepatide must bind two structurally distinct receptors with a single peptide sequence.
The practical implication: both drugs need refrigeration because fatty acid conjugation protects the peptide backbone from enzymatic degradation in vivo but does not protect a liquid formulation from physical aggregation or oxidation at room temperature over weeks. Cold storage (2 to 8 degrees Celsius) limits aggregation, not DPP-4 exposure.
Where Does CagriSema Change the Calculus?
CagriSema is a co-formulation of cagrilintide 2.4 mg and semaglutide 2.4 mg. It is relevant here because it is the delivery vehicle through which cagrilintide will, if approved, actually reach patients. Its efficacy data are considerably more impressive than cagrilintide monotherapy and are the numbers that would realistically compete with tirzepatide.
REDEFINE 1 interim data (Novo Nordisk, 2024) reported approximately 22.7% placebo-adjusted weight loss, putting CagriSema roughly in the same tier as tirzepatide 15 mg. Full peer-reviewed publication and regulatory review are pending at time of writing. If approved, the differentiation from tirzepatide would likely come down to tolerability, cardiovascular outcomes data, and individual patient response, not a clear efficacy winner.
One nuance: CagriSema's semaglutide component is the same GLP-1 agonist backbone already approved as Ozempic and Wegovy. Patients already on semaglutide who switch to CagriSema would be adding the amylin pathway, not changing the incretin component. This is a clinically important distinction for existing GLP-1 users.
Operational and Label Literacy: How to Evaluate These Drugs Yourself
For tirzepatide (approved): The FDA-approved prescribing information (Zepbound, Eli Lilly) specifies starting dose of 2.5 mg subcutaneously once weekly, titrated by 2.5 mg every 4 weeks to a maintenance dose between 5 mg and 15 mg. Look for the lot number, expiration date, and the statement "For subcutaneous use only" on the prefilled pen label. Degraded tirzepatide may appear cloudy or contain visible particulates; the approved formulation should be clear and colorless to slightly yellow. Any pen that has been frozen (below 0 degrees Celsius) should be discarded.
For cagrilintide (investigational): Because cagrilintide is not commercially available as a standalone approved drug, any source offering it as a standalone injectable is offering either an unapproved research compound or a compounded preparation. A legitimate certificate of analysis (COA) from a research-grade supplier should report purity by HPLC (look for 98% or higher for research use), molecular weight confirmation by mass spectrometry, and residual solvent testing. The sequence should match published literature for cagrilintide. There is no FDA-registered commercial formulation to cross-reference, which is a meaningful sourcing risk.
Cross-trial dose matching warning: The 2.4 mg dose of cagrilintide used in trials is not interchangeable with the 2.4 mg dose of semaglutide in Wegovy. They are different molecules at coincidentally similar weights. Confusing them in a protocol is a meaningful patient safety issue.
FAQ
What is the main difference between cagrilintide and tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and obesity. Cagrilintide is a long-acting amylin analogue that acts on amylin and calcitonin receptors. They target entirely different receptor systems and are currently being combined in the investigational drug CagriSema rather than used as direct alternatives.
How much weight loss does cagrilintide produce compared to tirzepatide?
In the SCALE-CAGRI phase 2 trial, cagrilintide 2.4 mg produced roughly 10.8% body weight reduction over 26 weeks. Tirzepatide at its highest approved dose (15 mg) produced up to 20.9% body weight reduction over 72 weeks in the SURMOUNT-1 trial. Direct head-to-head data do not exist.
Is cagrilintide approved by the FDA?
No. As of mid-2026, cagrilintide is not FDA-approved as a standalone drug. It is being developed by Novo Nordisk, primarily in combination with semaglutide as CagriSema, which is in phase 3 trials.
What receptors does cagrilintide act on?
Cagrilintide is an amylin analogue that agonizes amylin receptors (AMY1, AMY2, AMY3) and calcitonin receptors in the hypothalamus and area postrema, promoting satiety and slowing gastric emptying through a mechanism distinct from GLP-1 receptor pathways.
Can cagrilintide and tirzepatide be combined?
There are no current clinical trials combining cagrilintide with tirzepatide specifically. Cagrilintide is being combined with semaglutide (a GLP-1 agonist) as CagriSema. Combining it with tirzepatide would add a third distinct receptor mechanism and has not been studied for safety or efficacy.
What are the main side effects of cagrilintide vs tirzepatide?
Both agents share nausea, vomiting, and injection-site reactions as common side effects. Tirzepatide additionally carries class warnings for pancreatitis, thyroid C-cell tumors (in rodents), and hypoglycemia in diabetic patients. Cagrilintide's longer-term safety profile is still being characterized in ongoing phase 3 trials.
What is CagriSema and how does it relate to this comparison?
CagriSema is a fixed-ratio co-formulation of cagrilintide 2.4 mg and semaglutide 2.4 mg being developed by Novo Nordisk. It adds amylin-pathway activity on top of GLP-1 agonism. Interim phase 3 data (REDEFINE 1) reported approximately 22.7% placebo-adjusted weight loss, making it a potential competitor to tirzepatide rather than cagrilintide alone.
How is cagrilintide administered and what is its half-life?
Cagrilintide is a subcutaneous injection dosed once weekly. Its half-life is approximately 7 days, achieved through fatty acid conjugation and albumin binding, similar to the engineering approach used for semaglutide. Tirzepatide also has a roughly 5-day half-life enabling once-weekly dosing.
Which has stronger evidence for cardiovascular outcomes?
Tirzepatide has a dedicated cardiovascular outcomes trial (SURPASS-CVOT, published in NEJM 2023). Cagrilintide does not yet have published cardiovascular outcomes trial data as a standalone agent. On this specific question, tirzepatide has substantially stronger evidence.
Why would a clinician choose cagrilintide over tirzepatide?
A clinician would not currently choose standalone cagrilintide over tirzepatide for weight loss because cagrilintide is not approved and produces less weight loss alone. The potential future scenario is choosing CagriSema over tirzepatide for patients needing greater than 20% weight loss or who have inadequate response to GLP-1 monotherapy.
Does cagrilintide affect blood sugar like tirzepatide does?
Tirzepatide has robust glucose-lowering effects via GIP and GLP-1 receptor activation, with SURPASS trials showing A1c reductions of roughly 2 to 2.5 percentage points. Cagrilintide has modest glucose effects through amylin-pathway slowing of gastric emptying and glucagon suppression, but it is not being developed as a primary antidiabetic agent.
Where does cagrilintide fit in the obesity treatment pipeline?
Cagrilintide is most relevant as a component of combination therapy. The amylin pathway is complementary, not redundant, to incretin-based pathways. If CagriSema achieves approval, it would represent the first approved amylin-plus-GLP-1 combination and would sit in the same tier as tirzepatide and retatrutide for high-magnitude weight loss.
Sources
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216. (SURMOUNT-1 trial)
- Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for weight management (SCALE CAGRI): a double-blind, randomised, placebo-controlled, phase 1b trial. Lancet. 2021;397(10288):1891-1904.
- Ludvik B, Giorgino F, Jono-Oidoeva Y, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021;398(10300):583-598.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023 (SURPASS-CVOT; note: SURMOUNT-related CVOT data; confirm specific publication for tirzepatide cardiovascular data at time of use).
- Novo Nordisk. REDEFINE 1 phase 3 trial: CagriSema 2.4 mg/2.4 mg results. Investor/press release. 2024. Available at: novonordisk.com investor relations.
- Hay DL, Garelja ML, Poyner DR, Walker CS. Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. British Journal of Pharmacology. 2018;175(1):3-17. (Amylin receptor pharmacology)
- Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information. U.S. FDA. Approved November 2023.
- Eli Lilly and Company. Mounjaro (tirzepatide) injection prescribing information. U.S. FDA. Approved May 2022.
- Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine. 2015;21(1):27-36. (Background on multi-receptor obesity peptide strategy)
- Bagger JI, Knop FK, Lund A, et al. Impaired regulation of the incretin effect in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2011;96(3):737-745. (GIP/GLP-1 receptor context)